Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The purpose of this Phase IIb study is to evaluate the efficacy of the RSV vaccine candidate for the prevention of lower respiratory tract disease (LRTD) due to RSV. The study will enroll approximately 4500 adults aged 60 years and older in a 1:1 ratio to receive a single intra-muscular (IM) administration of either a pre-determined dose of the RSV vaccine candidate or placebo.
Epistemonikos ID: 7d576dc59c85b1ac5e80662b18df0925950d2090
First added on: May 15, 2024